Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)-Reference-Cited by-同舟云学术

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Published:2019-08-28 Issue:1 Volume:21 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

de Groot Stefanie, ,Pijl Hanno,Charehbili Ayoub,van de Ven Saskia,Smit Vincent T. H. B. M.,Meershoek-Klein Kranenbarg Elma,Heijns Joan B.,van Warmerdam Laurence J. C.,Kessels Lonneke W.,Dercksen M. Wouter,Pepels Manon J. A. E.,van Laarhoven Hanneke W. M.,Vriens Birgit E. P. J.,Putter Hein,Fiocco Marta,Liefers Gerrit-Jan,van der Hoeven Jacobus J. M.,Nortier Johan W. R.,Kroep Judith R.

Funder

dutch cancer society

Amgen

Sanofi

Amgen Nederland

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-019-1180-6.pdf

Reference35 articles.

1. Charehbili A, Fontein DB, Kroep JR, et al. Can zoledronic acid be beneficial for promoting tumor response in breast cancer patients treated with neoadjuvant chemotherapy? J Clin Med. 2013;2:188–200.

2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032–45.